This post was originally published on this site
SUDBURY, Mass., April 22, 2025 /PRNewswire/ — Gentuity, LLC, a leader in intravascular High Frequency Optical Coherence Tomography (HF-OCT) imaging technology, is pleased to announce the strategic expansion of its senior leadership team with the addition of three highly accomplished professionals: Jason Rudy, Raj Kasbekar, and Alex Yildizyan. These key appointments mark a pivotal moment for Gentuity as the company enters a new phase of accelerated growth, innovation, and global market expansion.
Strengthening Leadership for Next-Generation Innovation
Jason Rudy joins Gentuity as a seasoned marketing and sales leader with over 20 years of experience in interventional cardiology. Jason played a key role at St. Jude Medical in bringing the first coronary OCT platform to market. With additional leadership roles at Abbott, Biotronik, and Philips, Jason brings with him a deep understanding of commercial strategy and a demonstrated track record of driving clinical adoption of new technologies.
“I’m passionate about providing greater access to best-in-class medical devices that improve outcomes and reduce costs,” said Jason “Gentuity’s HF-OCT platform is poised to transform intravascular imaging, and I’m thrilled to help shape its future.”
Alex Yildizyan brings over a decade of research and development leadership experience from Glaukos Corp., where he most recently served as Vice President of R&D for Biophotonics and Combination Products. Known for his collaborative and people-first approach to innovation, Alex will guide Gentuity’s R&D team in transforming complex challenges into commercial success.
“My passion lies in mentoring teams and bringing groundbreaking technology to life,” said Yildizyan. “The mission at Gentuity strongly aligns with my personal commitment to advancing meaningful medical solutions.”
Raj Kasbekar, an expert in biomedical engineering, regulatory affairs, and clinical strategy, joins Gentuity after a 16-year tenure at Kaz USA (Helen of Troy), where he helped scale the company from a $300M business to a $2B industry leader. With four patents, numerous publications, and a PhD in Biomedical Engineering with a concentration in AI/ML applications, he brings deep expertise to Gentuity’s product development and global expansion efforts.
“The potential for expanding HF-OCT technology into new geographies and indications is vast,” said Kasbekar. “I’m excited to contribute to Gentuity’s growth by applying strategic, science-backed leadership.”
Positioned for the Future
“These exceptional leaders bring world-class expertise and a passion for innovation that will further strengthen the Gentuity team,” said Desmond Adler, President of Gentuity. “Their impact will be felt immediately as we expand the reach of our HF-OCT platform and deliver breakthrough technologies to clinicians and patients around the world.” Gentuity plans to continue building on the success of the recently approved Prime Vis-Rx catheter, which is the world’s smallest and most deliverable intravascular imaging device and is the only such product specifically indicated for pre-interventional use.
About Gentuity
Based in Sudbury, MA, Gentuity is a commercial-stage medical technology company pioneering next-generation intravascular imaging devices. The Gentuity High-Frequency OCT Imaging System is the first commercially available system to deliver Total Vessel Imaging with a 1.8F micro-imaging catheter in less than 1 second. The company is dedicated to crossing new frontiers in cardiovascular care so patients can focus on living.
For media inquiries, please contact:
Candace Copher
[email protected]
Gentuity, LLC
SOURCE Gentuity, LLC
